CSL to buy Vifor for $11.7B in biopharma’s largest M&A deal this year
In a move to diversify its business, Australian biopharma CSL has agreed to acquire Vifor Pharma for $11.7 billion. The deal would give CSL—heavily dependent on vacci...
Continue Reading →
